Gegenanzeigen · Zeposia
Zeposia 0.23 mg hard capsules Zeposia 0.46 mg hard capsules Zeposia 0.92 mg hard capsules · Abschnitt 4.3 · PDF-Seite 4
HOS-142244 · Präparat HOS-098792
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. • Immunodeficient state predisposing to systemic opportunistic infections (see section 4.4). • Patients who in the last 6 months experienced myocardial infarction (MI), unstable angina, stroke, transient ischaemic attack (TIA), decompensated heart failure requiring hospitalisation or New York Heart Association (NYHA) Class III/IV heart failure. • Patients with history or presence of second-degree atrioventricular (AV) block Type II or third- degree AV block or sick sinus syndrome unless the patient has a functioning pacemaker. • Severe active infections, active chronic infections such as hepatitis and tuberculosis (see section 4.4). • Active malignancies. • Severe hepatic impairment (Child-Pugh class C). • During pregnancy and in women of childbearing potential not using effective contraception (see sections 4.4 and 4.6).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-03T10:34:00Z · SHA-256 e1efa1853d4dbc887f7da13387736c7007c19f29d49a626a00d40b88c00a6a21 · Passage 55dfa92520cfb56c147894f9ac8590173c4a98d8fee35189b3948afe54d824a7 · Zeichen 0–989 im Abschnitt